- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Europe-led Lixiana email/video campaign ran without UK certification. Panel found missing AE reporting statement/date, incomplete PI (no UK cost), unsubstantiated ‘proven/ideal’…
Cosopt wrap-around on The Ophthalmologist was visible through transparent packaging and printed without the non-proprietary name. No breach for “overleaf” PI reference…
A nurse alleged a Sanofi rep emailed Toujeo Coach webinar invites without consent and said email activity was tracked. Panel found insufficient…
Sanofi’s Toujeo DoubleStar slide deck wrongly claimed “fewer prescriptions”. PMCPA ruled the claim misleading and unsubstantiated, and found inadequate rep briefing. No…
A member of the public alleged GDPR-related issues in Sanofi’s medical information interactions (call recording notice, email retention, and “offline” discussions). The…
GSK’s severe asthma webinar registration page listed PI links for Trelegy, Anoro and Incruse (COPD-only), implying asthma use. Breaches of Clauses 3.2,…
A GP complaint (via MHRA) about a Macrobid promotional email. PMCPA ruled the “1 in 3 adults will fail treatment with trimethoprim”…
Two ophthalmic journal ads and an HCP webpage used the strapline “Powerful. Proven. Targeted.” for Lucentis. PMCPA ruled “Powerful” ambiguous (breach), but…
Anonymous employee alleged Toujeo/Suliqua “advocate” programme induced prescribing and misused HCP data. Panel found no inducement/GDPR breach, but ruled internal templates were…
A senior employee’s LinkedIn post and a Sunday Times interview/press release were ruled promotional, encouraging patient requests and promoting Enhertu in an…
A StritVit D3 poster claimed “suitable for vegetarians” despite bovine bone gelatin in capsules. PMCPA ruled the claim misleading and found breaches…
Complaint about use of ‘unique’ in a Trajenta (linagliptin) HCP digital banner claim. Panel ruled no breach of Clause 14.4, accepting the…
Complaint alleged a Lixiana initiation “webinar” omitted hepatic monitoring/contraindications and included a dosing interaction error. Panel found no breach as content was…
PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated ‘energy’ claim, ‘best’ implying superiority, and unqualified renal…
Small Pharma’s open-access website discussed psychedelic pipeline programmes using strong, unqualified language without clearly identifying the intended audience. PMCPA ruled a breach…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.